^
BIOMARKER:

CD20 positive

i
Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
rituximab + ibritumomab tiuxetan
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
rituximab
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-abbs
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Burkitt Lymphoma
rituximab
Sensitive
:
A1
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
obinutuzumab
Sensitive
:
A1
CD20 positive
Acute Lymphocytic Leukemia
rituximab
Sensitive
:
A2
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + copanlisib
Sensitive
:
B
CD20 positive
Lymphoma
rituximab + copanlisib
Sensitive
:
B
CD20 positive
Follicular Lymphoma
rituximab-abbs
Sensitive
:
C1
CD20 positive
Diffuse Large B Cell Lymphoma
GEN-3013
Sensitive
:
C2
CD20 positive
Follicular Lymphoma
GEN-3013
Sensitive
:
C2
CD20 positive
Lymphoma
copanlisib
Sensitive
:
C2
CD20 positive
Chronic Lymphocytic Leukemia
FCR
Sensitive
:
C3
CD20 positive
Diffuse Large B Cell Lymphoma
venetoclax + obinutuzumab
Sensitive
:
C3
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + ALX148
Sensitive
:
C3
CD20 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
C3
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab + PF-05082566
Sensitive
:
C3
CD20 positive
Follicular Lymphoma
MB-106
Sensitive
:
C3
CD20 positive
B Acute Lymphoblastic Leukemia
ofatumumab
Sensitive
:
C3
CD20 positive
Mantle Cell Lymphoma
GEN-3013
Sensitive
:
C3
CD20 positive
Follicular Lymphoma
rituximab + lenalidomide + GEN-3013
Sensitive
:
C3
CD20 positive
Follicular Lymphoma
rituximab + CC-122
Sensitive
:
C3